Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer
Sponsor: National Cancer Institute (NCI)
This observational or N/A phase trial investigates Metastatic Esophageal Adenocarcinoma and Metastatic Esophageal Squamous Cell Carcinoma and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 52 recorded versions since 2010 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Study Description(click to expand)PRIMARY OBJECTIVES: I. To evaluate the progression-free survival of paclitaxel plus cixutumumab (IMC-A12) versus paclitaxel alone as second-line therapy in patients with metastatic esophagus or gastroesophageal (GE) junction cancer. SECONDARY OBJECTIVES: I. To evaluate the overall survival of paclitaxel plus cixutumumab (IMC-A12) versus paclitaxel alone in this patient population. II. To evaluate the response rate of paclitaxel plus cixutumumab (IMC-A12) versus paclitaxel alone in this patient population. III. To evaluate the toxicity of cixutumumab (IMC-A12) plus paclitaxel versus paclitaxel alone in this patient population. IV. Exploratory analyses will assess potentially relevant cixutumumab (IMC-A12) pharmacodynamic biomarkers obtained from serum samples, including but not limited to, insulin-like growth factor (IGF)-I, IGF-II, insulin-like growth factor binding protein (IGFBP)-2, and IGFBP-3. OUTLINE: Patients are equally randomized to 1 of 2 treatment arms. ARM I: Patients receive paclitaxel intravenously (IV) over 1 hour at a dose of 80 mg/m\^2 on days 1, 8, and 15 of every 28 day cycle. ARM II: Patients receive cixutumumab IV over 1 hour at a dose of 10 mg/kg on days 1 and 15 of every 28 day cycle and paclitaxel as in Arm I. In both arms, courses repeat every 28 days in the absence of disease progression...
PRIMARY OBJECTIVES:
I. To evaluate the progression-free survival of paclitaxel plus cixutumumab (IMC-A12) versus paclitaxel alone as second-line therapy in patients with metastatic esophagus or gastroesophageal (GE) junction cancer.
SECONDARY OBJECTIVES:
I. To evaluate the overall survival of paclitaxel plus cixutumumab (IMC-A12) versus paclitaxel alone in this patient population.
II. To evaluate the response rate of paclitaxel plus cixutumumab (IMC-A12) versus paclitaxel alone in this patient population.
III. To evaluate the toxicity of cixutumumab (IMC-A12) plus paclitaxel versus paclitaxel alone in this patient population.
IV. Exploratory analyses will assess potentially relevant cixutumumab (IMC-A12) pharmacodynamic biomarkers obtained from serum samples, including but not limited to, insulin-like growth factor (IGF)-I, IGF-II, insulin-like growth factor binding protein (IGFBP)-2, and IGFBP-3.
OUTLINE: Patients are equally randomized to 1 of 2 treatment arms.
ARM I: Patients receive paclitaxel intravenously (IV) over 1 hour at a dose of 80 mg/m\^2 on days 1, 8, and 15 of every 28 day cycle.
ARM II: Patients receive cixutumumab IV over 1 hour at a dose of 10 mg/kg on days 1 and 15 of every 28 day cycle and paclitaxel as in Arm I.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years.
Status Flow
Change History
52 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE2 → None
-
Dec 2025 — May 2026 [monthly]
Active Not Recruiting PHASE2
-
Oct 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 47 earlier versions
-
May 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jan 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — May 2024 [monthly]
Active Not Recruiting PHASE2
-
Dec 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE2
-
Dec 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
May 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
-
Nov 2021 — May 2022 [monthly]
Active Not Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
May 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Jul 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This randomized phase II trial studies how well paclitaxel with or without cixutumumab works in treating patients with esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cixutumumab may kill cancer cells by blocking the action of a protein needed for cancer cell growth. Giving paclitaxel with or without cixutumumab may kill more tumor cells.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .